Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality.

Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant (2013) 1.60

Specific infectious complications after stem cell transplantation. Support Care Cancer (2003) 0.78

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood (1995) 2.43

Detection and identification of fungal pathogens in blood by using molecular probes. J Clin Microbiol (1997) 5.86

Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys (2000) 5.06

Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia (2010) 3.31

Quantification of fungal DNA by using fluorescence resonance energy transfer and the light cycler system. J Clin Microbiol (2000) 3.02

Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97

Pure red-cell aplasia associated with clonal expansion of granular lymphocytes expressing killer-cell inhibitory receptors. N Engl J Med (1999) 2.89

The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood (1998) 2.78

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

Survival after bone marrow transplantation from cytomegalovirus seropositive sibling donors. Lancet (2001) 2.77

Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Lett (1997) 2.72

Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64

Identification of and spatio-temporal differences between microbial assemblages from two neighboring sulfurous lakes: comparison by microscopy and denaturing gradient gel electrophoresis. Appl Environ Microbiol (2000) 2.51

[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med Wochenschr (1974) 2.50

Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood (1995) 2.43

Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J (1997) 2.33

Modification of human cytomegalovirus tropism through propagation in vitro is associated with changes in the viral genome. J Gen Virol (1999) 2.33

Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett (1997) 2.15

Comparison of different methods for extraction of DNA of fungal pathogens from cultures and blood. J Clin Microbiol (1997) 2.13

Influence of lipid/peptide hydrophobic mismatch on the thickness of diacylphosphatidylcholine bilayers. A 2H NMR and ESR study using designed transmembrane alpha-helical peptides and gramicidin A. Biochemistry (1998) 2.07

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood (2000) 2.00

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant (2009) 2.00

Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood (1994) 1.95

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Blood (2001) 1.93

Contaminations occurring in fungal PCR assays. J Clin Microbiol (1999) 1.86

Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet (1996) 1.85

Deposition of the terminal C5b-9 complement complex in infarcted areas of human myocardium. J Immunol (1986) 1.83

Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant (2005) 1.79

Validity of western immunoblot band patterns in the serodiagnosis of Lyme borreliosis. J Clin Microbiol (1991) 1.79

Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant (2008) 1.78

Human signal-regulatory protein is expressed on normal, but not on subsets of leukemic myeloid cells and mediates cellular adhesion involving its counterreceptor CD47. Blood (1999) 1.77

Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol (2003) 1.75

Cell types involved in replication and distribution of human cytomegalovirus. Adv Virus Res (1996) 1.72

Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70

Necrotizing lymphadenitis: Kikuchi--Fujimoto disease alias lupus lymphadenitis? Lupus (2009) 1.67

Detection of PCR-amplified fungal DNA by using a PCR-ELISA system. Med Mycol (1998) 1.61

Monocyte-derived dendritic cells are permissive to the complete replicative cycle of human cytomegalovirus. J Gen Virol (2000) 1.60

Kinetics of the antibody response against human cytomegalovirus-specific proteins in allogeneic bone marrow transplant recipients. J Infect Dis (1998) 1.58

Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. J Infect Dis (1997) 1.57

Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant (2008) 1.56

Exploring the genetic link between RLS and ADHD. J Psychiatr Res (2009) 1.55

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant (2006) 1.53

Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics (2001) 1.53

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut (1996) 1.53

Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood (1999) 1.52

Surface phenotype analysis of human monocyte to macrophage maturation. J Leukoc Biol (1990) 1.52

The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res (2001) 1.50

Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. Blood (1992) 1.48

Early detection of aspergillus infection after allogeneic stem cell transplantation by polymerase chain reaction screening. J Infect Dis (2000) 1.47

Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer (2002) 1.46

Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone Marrow Transplant (2007) 1.46

Primary central nervous system (CNS) lymphoma in immunocompetent patients. Ann Hematol (2002) 1.46

Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene (2001) 1.46

Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant (2009) 1.44

Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells. Blood (2001) 1.44

[Regional adjuvant therapy in colorectal liver metastases: requirements for clinical therapy studies from the statistical viewpoint]. Zentralbl Chir (1995) 1.44

In vivo effects of interleukin-6 on thrombopoiesis in healthy and irradiated primates. Blood (1992) 1.44

Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant (2009) 1.42

Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia (2010) 1.41

Aerobic exercise in the rehabilitation of cancer patients after high dose chemotherapy and autologous peripheral stem cell transplantation. Cancer (1997) 1.41

Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant (2004) 1.40

Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation (2001) 1.39

Systemic effects and side effects of interstitial techniques used in liver tissue. J Am Coll Surg (1999) 1.39

Familial clustering of infantile cirrhosis in Northern Germany: A clue to the etiology of idiopathic copper toxicosis. J Pediatr (1999) 1.39

Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia (1996) 1.38

[68-year-old female patient with dyspnea and hypokalemic hypertension]. Internist (Berl) (2007) 1.38

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia (2009) 1.38

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis (2009) 1.35

Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry (2010) 1.33

Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol (2000) 1.33

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia (2012) 1.33

Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene (2009) 1.32

Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood (1997) 1.30

Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept (2001) 1.30